July 30, 2021 - ROSEN LOGO.jpg
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
February 14, 2023 20:40 ET | The Rosen Law Firm PA
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
July 30, 2021 - ROSEN LOGO.jpg
TOP RANKED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
February 09, 2023 15:33 ET | The Rosen Law Firm PA
NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
January 17, 2023 18:50 ET | The Rosen Law Firm PA
NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
BES_Mark.jpg
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm
January 11, 2023 21:00 ET | Bragar Eagel & Squire
NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals,...
July 30, 2021 - ROSEN LOGO.jpg
PHAT INVESTOR NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
January 11, 2023 14:48 ET | The Rosen Law Firm PA
NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
November 23, 2022 18:07 ET | The Rosen Law Firm PA
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – PHAT
November 02, 2022 14:55 ET | The Rosen Law Firm PA
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
August 06, 2022 13:16 ET | The Rosen Law Firm PA
NEW YORK, Aug. 06, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
January 19, 2021 08:30 ET | Phathom Pharmaceuticals
Topline results expected in second quarter of 2021NDA submission for H. pylori expected in second half of 2021 FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals,...
Phathom_Pharm_Logo_RGB.png
Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences
November 27, 2020 08:00 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...